HSCS · XBRL financial data

HeartSciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (HSCS's year ends in late June)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY25Jul 31, 2025	Q2 FY25Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Jun 30, 2026	Q1 FY27Jul 31, 2026
Revenue from contracts with customers	4	15	0*	—	—	0	4*	2	2	0	—	2
Cost of revenue	2	5	0*	—	—	0	2*	1	1	0	—	1
Gross profit	2	10	0*	—	—	0	2*	1	1	0	—	1
Research and development	757	510	1,046*	1,225	1,199	1,033	929*	997	727	639	—	907
Selling, general and administrative	815	1,026	834*	851	786	1,338	994*	878	1,348	1,290	—	2,034
Total operating expenses	1,572	1,536	1,880*	2,076	1,985	2,371	1,923*	1,875	2,075	1,929	—	2,940
Operating income (loss)	(1,570)	(1,525)	(1,880)*	(2,076)	(1,985)	(2,371)	(1,920)*	(1,874)	(2,073)	(1,929)	—	(2,939)
Interest expense	178	118	21*	23	118	179	181*	184	280	62	—	235
Other income (expense)	—	—	—	—	—	15	7*	3	—	5	—	2
Income tax expense (benefit)	—	—	—	—	—	—	year only	—	—	—	—	—
Net income (loss)	(1,748)	(1,644)	(1,846)*	(2,052)	(2,083)	(2,536)	(2,094)*	(2,055)	(2,351)	(1,985)	—	(3,172)
Earnings per share, basic‡ USD per share	(16.00)	(3.00)	—	(2.64)	(2.27)	(2.57)	(1.95)*	(1.58)	(0.85)	(0.63)	—	(0.86)
Earnings per share, diluted‡ USD per share	(16.00)	(3.00)	—	(2.64)	(2.27)	(2.57)	(1.95)*	(1.58)	(0.85)	—	—	—
Weighted average shares, basic‡ thousands of shares	109	538	—	778	917	986	1,076*	1,304	2,780	3,162	—	3,669
Weighted average shares, diluted‡ thousands of shares	109	538	—	778	917	986	1,076*	1,304	2,780	—	—	—

‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (October 2025); filings made before it reported them unadjusted.

Fiscal quarters (HSCS's year ends in late June)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY25Jul 31, 2025	Q2 FY25Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Jun 30, 2026	Q1 FY27Jul 31, 2026
Cash and cash equivalents	100	7,076	5,808	4,340	4,052	2,597	1,098	2,792	1,951	3,397	1,657	30
Accounts receivable	4	15	—	—	—	—	4	—	—	0	0	—
Inventory	675	670	629	643	653	652	650	650	657	657	656	403
Total current assets	1,812	8,691	7,354	6,075	5,689	3,629	2,171	4,417	3,793	5,099	2,583	812
Property and equipment, net	53	58	98	86	77	71	64	56	53	46	39	33
Right-of-use asset	503	483	462	441	418	395	372	347	322	295	268	240
Total assets	2,368	10,801	9,503	8,191	7,777	5,704	4,223	6,437	5,996	7,555	5,263	3,737
Accounts payable	1,088	415	448	397	277	405	319	283	317	411	318	1,023
Accrued liabilities	773	584	398	331	370	316	506	599	311	—	—	—
Total current liabilities	3,531	1,706	1,752	1,352	3,303	3,571	3,703	3,015	1,566	4,269	4,861	5,633
Lease liability, non-current	487	461	434	406	376	346	315	282	247	212	176	137
Total liabilities	4,018	2,167	2,186	2,257	3,761	3,917	4,018	3,296	1,814	4,902	5,037	5,770
Accumulated deficit	(63,872)	(65,516)	(67,362)	(69,414)	(71,497)	(74,033)	(76,128)	(78,183)	(80,533)	(82,519)	(85,270)	(88,442)
Total stockholders' equity	(1,650)	8,634	7,317	5,934	4,017	1,787	205	3,141	4,182	2,652	226	(2,033)
Total liabilities and equity	2,368	10,801	9,503	8,191	7,777	5,704	4,223	6,437	5,996	7,555	5,263	3,737
Common shares outstanding (cover page)‡ thousands of shares	636	656	856	911	980	1,081	1,934	2,648	3,178	3,185	3,899	4,800

‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (October 2025); filings made before it reported them unadjusted.

Fiscal quarters (HSCS's year ends in late June)

In thousands of dollars	Q2 FY24Oct 31, 2023	Q3 FY24Jan 31, 2024	Q4 FY24Apr 30, 2024	Q1 FY25Jul 31, 2024	Q2 FY25Oct 31, 2024	Q3 FY25Jan 31, 2025	Q4 FY25Apr 30, 2025	Q1 FY25Jul 31, 2025	Q2 FY25Oct 31, 2025	Q3 FY26Jan 31, 2026	Q4 FY26Jun 30, 2026	Q1 FY27Jul 31, 2026
Net income (loss)	(1,748)	(1,644)	(1,846)*	(2,052)	(2,083)	(2,536)	(2,094)*	(2,055)	(2,351)	(1,985)	—	(3,172)
Stock-based compensation	106*	96*	78*	55	45*	55*	96*	175	437*	376*	—	739
Net cash from operating activities	(988)*	(2,141)*	(1,536)*	(2,019)	(2,184)*	(1,620)*	(1,591)*	(1,953)	(2,334)*	(1,463)*	—	(1,319)
Purchases of property and equipment	2*	9*	49*	—	—	0*	0*	—	—	(9)*	—	—
Net cash from investing activities	(2)*	(9)*	(110)*	(1)	(6)*	(16)*	(8)*	(1)	(16)*	(28)*	—	(280)
Proceeds from issuing common stock	—	—	—	—	—	—	171*	0	—	—	—	10
Net cash from financing activities	515*	9,127*	377*	552	1,902*	180*	100*	3,648	1,509*	2,936*	—	(28)
Net change in cash	(476)*	6,976*	(1,269)*	(1,468)	(288)*	(1,456)*	(1,498)*	1,694	(841)*	1,446*	—	(1,627)

SIC 6199 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 6199 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
HeartSciences	30	2.1	(1,319)	4.8M	0.0 quarters	Q1 FY27 10-QJul 31, 2026
Applied Dna Sciences	3,761	not reported	not reported	6.2M	—	Q3 FY26 10-QJun 30, 2026
ZeroStack	2,640	13,658	1,373*	17.5M	—	Q2 FY26 10-QJun 30, 2026
Marblegate Capital	7,312	16,681	(5,202)*	73.9M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Marygold Companies	2,880	6,925*	129*	42.7M	—	Q4 FY26 10-KJun 30, 2026
Beneficient	5,582	12,165	(4,105)	not reported	1.4 quarters	Q1 FY27 10-QJun 30, 2026
Soluna Holdings	113,364	15,060	(5,183)*	244.6M	21.9 quarters	Q2 FY26 10-QJun 30, 2026
FG Nexus	24,923	242	(4,543)*	5.1M	5.5 quarters	Q2 FY26 10-QJun 30, 2026
Axe Compute	21,906	not reported	not reported	11.6M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.